MediciNova is a La Jolla, California drug developer working on experimental treatments for diseases such as multiple sclerosis and ALS. It last closed at $1.34 on Nov 17, up 0.00% on the day.
Only 1 firm rated MNOV in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 347.8% upside
Based on 1 analyst who set a price target on MNOV in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $1.34.
Low $6.00Avg $6.00High $6.00
Blue marker: last close $1.34
Highest target$6.00
Average target$6.00
Lowest target$6.00
Latest rating changes
Roth CapitalInitiated
Sep 17Buy$6
Maxim GroupReinstated
Mar 23Buy$6
Date
Firm
Action
Rating
Price target
Sep 17
Roth Capital
Initiated
Buy
$6
Mar 23
Maxim Group
Reinstated
Buy
$6
Loading…
Technical Analysis
MNOV · as of the Nov 17 close · updated after every close
Turning down, nearing oversold
The stock is 6% below its 20 day and 32% below its 50 day average. It is 12% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 35), near oversold. The nearest support is the Pivot S1 at $1.32, and the nearest resistance the Pivot at $1.36.
Short trendBearish
Long trendNeutral
MomentumFading
StretchNear oversold
VolatilityNormal, 6.2%/day
Key levels
$3.9052 week high+191.0%
$1.7750 day average+32.1%
$1.58100 day average+17.9%
$1.50200 day average+11.9%
$1.4120 day average+5.2%
$1.37Pivot R1+2.2%
$1.37Swing high (Jun 3)+2.2%
$1.36Pivot+1.5%
$1.34Last close
$1.32Pivot S1−1.5%
$1.31Swing low (Jul 17)−2.2%
$1.2252 week low−9.0%
Indicators
RSI (14)
35.10
Weak, oversold below 30
Neutral
MACD
-0.07
Above its signal line
Bullish
Stochastic
3.0
Near the bottom of its range
Oversold
ADX (14)
17.5
No clear trend
Williams %R
-100.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-157.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−7.6%
Change over 10 sessions
Bearish
ATR (14)
$0.08
Typical daily range, 6.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 21.1%/day
Key levels
$3.9052 week high+191.0%
$1.7750 day average+32.1%
$1.58100 day average+17.9%
$1.50200 day average+11.9%
$1.4120 day average+5.2%
$1.37Pivot R1+2.2%
$1.37Swing high (Jun 3)+2.2%
$1.36Pivot+1.5%
$1.34Last close
$1.32Pivot S1−1.5%
$1.31Swing low (Jul 17)−2.2%
$1.2252 week low−9.0%
Indicators
RSI (14)
45.57
Middle of its range
Neutral
MACD
-0.01
Below its signal line
Bearish
Stochastic
3.8
Near the bottom of its range
Oversold
ADX (14)
30.1
Trending up
Williams %R
-98.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-53.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−26.0%
Change over 10 sessions
Bearish
ATR (14)
$0.28
Typical daily range, 21.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MNOV
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how MNOV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow MNOV usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How MNOV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MNOV is in one of them and how their past MNOV trades turned out.
MediciNova is a biopharmaceutical company based in La Jolla, California. It develops drug candidates for serious diseases that lack adequate treatment options. Its main candidates are MN-166, also called ibudilast, which is being studied for conditions such as progressive multiple sclerosis and amyotrophic lateral sclerosis, and MN-001, also called tipelukast, which is being studied for fibrotic and metabolic disorders such as fatty liver disease. The company's commercial focus is the United States market.